Cool_老虎社区_美港股上老虎

ItsRileyReid
2021-10-26

Cool

Lilly raises 2021 outlook on higher COVID-19 drugs sales

Oct 26 (Reuters) - Eli Lilly and Co raised its full-year profit and revenue forecasts on Tuesday, ma

Lilly raises 2021 outlook on higher COVID-19 drugs sales

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":852355939,"tweetId":"852355939","gmtCreate":1635246101269,"gmtModify":1635246168815,"author":{"id":3575184455730384,"idStr":"3575184455730384","authorId":3575184455730384,"authorIdStr":"3575184455730384","name":"ItsRileyReid","avatar":"https://static.tigerbbs.com/2104a50c539eebad8cbb8bb664fa8232","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":29,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Cool</p></body></html>","htmlText":"<html><head></head><body><p>Cool</p></body></html>","text":"Cool","highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/852355939","repostId":2178240346,"repostType":4,"repost":{"id":"2178240346","kind":"news","pubTimestamp":1635244260,"share":"https://www.laohu8.com/m/news/2178240346?lang=&edition=full","pubTime":"2021-10-26 18:31","market":"us","language":"en","title":"Lilly raises 2021 outlook on higher COVID-19 drugs sales","url":"https://stock-news.laohu8.com/highlight/detail?id=2178240346","media":"StreetInsider","summary":"Oct 26 (Reuters) - Eli Lilly and Co raised its full-year profit and revenue forecasts on Tuesday, ma","content":"<p>Oct 26 (Reuters) - Eli Lilly and Co raised its full-year profit and revenue forecasts on Tuesday, mainly due to higher sales of its COVID-19 antibody therapies, and the drugmaker said it has initiated a rolling submission for its experimental Alzheimer's treatment.</p>\n<p>Demand for Lilly's COVID-19 antibody therapies, bamlanivimab and etesevimab, rose during the last three months as the spread of the Delta variant fueled a sharp rise in infections and hospitalizations in areas with low vaccination rates. The antibody treatments brought in $217 million in the third quarter, up from $149 million in the second quarter.</p>\n<p>The U.S. government in September bought 388,000 additional doses of Lilly's etesevimab, of which Lilly said it shipped about 250,000 doses in the three months ended Sept. 30.</p>\n<p>The company said it now expected adjusted earnings per share between $$7.95 and $8.05 this year, up from its previous forecast of $7.80 to $8.00.</p>\n<p>Excluding one-off items, Eli Lilly earned $1.94 per share, missing analyst estimates of $1.98 per share, on higher research and development expenses including for the COVID-19 drugs.</p>\n<p>Lilly&nbsp;shares&nbsp;rose&nbsp;more&nbsp;than&nbsp;1%&nbsp;in&nbsp;premarket&nbsp;trading.</p>\n<p><img src=\"https://static.tigerbbs.com/810de663a911c7baf185bbd4108e8cd6\" tg-width=\"879\" tg-height=\"581\" width=\"100%\" height=\"auto\"></p>\n<p></p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Lilly raises 2021 outlook on higher COVID-19 drugs sales</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLilly raises 2021 outlook on higher COVID-19 drugs sales\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-26 18:31 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=19103484><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Oct 26 (Reuters) - Eli Lilly and Co raised its full-year profit and revenue forecasts on Tuesday, mainly due to higher sales of its COVID-19 antibody therapies, and the drugmaker said it has initiated...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=19103484\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LLY":"礼来"},"source_url":"https://www.streetinsider.com/dr/news.php?id=19103484","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2178240346","content_text":"Oct 26 (Reuters) - Eli Lilly and Co raised its full-year profit and revenue forecasts on Tuesday, mainly due to higher sales of its COVID-19 antibody therapies, and the drugmaker said it has initiated a rolling submission for its experimental Alzheimer's treatment.\nDemand for Lilly's COVID-19 antibody therapies, bamlanivimab and etesevimab, rose during the last three months as the spread of the Delta variant fueled a sharp rise in infections and hospitalizations in areas with low vaccination rates. The antibody treatments brought in $217 million in the third quarter, up from $149 million in the second quarter.\nThe U.S. government in September bought 388,000 additional doses of Lilly's etesevimab, of which Lilly said it shipped about 250,000 doses in the three months ended Sept. 30.\nThe company said it now expected adjusted earnings per share between $$7.95 and $8.05 this year, up from its previous forecast of $7.80 to $8.00.\nExcluding one-off items, Eli Lilly earned $1.94 per share, missing analyst estimates of $1.98 per share, on higher research and development expenses including for the COVID-19 drugs.\nLilly shares rose more than 1% in premarket trading.","news_type":1},"isVote":1,"tweetType":1,"viewCount":709,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":4,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}

Lilly raises 2021 outlook on higher COVID-19 drugs sales

评论（2）

热议股票